Novartis has agreed to acquire Anthos Therapeutics, a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathway. Abelacimab is currently in Phase III development, with the lead indication for prevention of stroke and systemic embolism in patients with atrial fibrillation. Novartis will make an upfront payment of $925 million […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!